There are 2 references here from NICE not to offer ADs (you can read it in the guidance- I've just copied and pasted it.)
1.4 Managing short-term menopausal symptoms
The recommendations in this section are not intended for women with premature ovarian insufficiency (see recommendations on the management of premature ovarian insufficiency).
1.4.1Adapt a woman's treatment as needed, based on her changing symptoms.
Vasomotor symptoms
1.4.2Offer women HRT for vasomotor symptoms after discussing with them the short-term (up to 5 years) and longer-term benefits and risks. Offer a choice of preparations as follows:
oestrogen and progestogen to women with a uterus
oestrogen alone to women without a uterus.
1.4.3Do not routinely offer selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs) or clonidine as first-line treatment for vasomotor symptoms alone.
1.4.4Explain to women that there is some evidence that isoflavones or black cohosh may relieve vasomotor symptoms. However, explain that:
multiple preparations are available and their safety is uncertain
different preparations may vary
interactions with other medicines have been reported.
Psychological symptoms
1.4.5Consider HRT to alleviate low mood that arises as a result of the menopause.
1.4.6Consider CBT to alleviate low mood or anxiety that arise as a result of the menopause.
1.4.7Ensure that menopausal women and healthcare professionals involved in their care understand that there is no clear evidence for SSRIs or SNRIs to ease low mood in menopausal women who have not been diagnosed with depression (see the NICE guideline on depression in adults).